drugset / Trial / NCT04984954

Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction

NCT04984954 ↗

Phase 4 Unknown 264 enrolled Shanghai Hutchison Pharmaceuticals Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled clinical multicenter study.At the same time, the effects of exercise tolerance and quality of life were also observed.

Timeline

Start
2021-01-28
Primary completion
2023-12-31
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MUSK pill Unknown 4 unknown —